Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD

Blood (2015) 126 (23): 3174.

https://doi.org/10.1182/blood.V126.23.3174.3174

Published: 2015

Journal Articles

Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma

Prashant Kapoor, MD, Morie A Gertz, M.D., Angela Dispenzieri, MD, Martha Q Lacy, MD, David Dingli, M.D., Ph.D., Suzanne R Hayman, MD, Francis K Buadi, M.D., Stephen Russell, MD, PhD, Yi Lin, MD, Thomas E. Witzig, MD, John A Lust, MD, PhD, Steven R Zeldenrust, MD, PhD, Philip R. Greipp, MD, Robert A. Kyle, MD, Vincent Rajkumar, MD, Shaji K. Kumar, MD

Blood (2012) 120 (21): 1988.

https://doi.org/10.1182/blood.V120.21.1988.1988

Published: 2012

Journal Articles

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Blood (2012) 119 (21): 4860–4867.

https://doi.org/10.1182/blood-2012-01-407791

Published: 2012

Journal Articles

Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)

Zhihui Xie, Chandra C. Ghosh, Roshni Patel, Shoko Iwaki, Donna Gaskins, Celeste Nelson, Nina Jones, Philip R. Greipp, Samir M. Parikh, Kirk M. Druey

Blood (2012) 119 (18): 4321–4332.

https://doi.org/10.1182/blood-2011-08-375816

Published: 2012

Includes: Supplemental data

Journal Articles

Immunoglobulin D amyloidosis: a distinct entity

Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Angela Dispenzieri, Philip R. Greipp, Shaji K. Kumar, Martha Q. Lacy, John A. Lust, Nelson Leung, S. Vincent Rajkumar, Stephen J. Russell, Steven R. Zeldenrust, Joseph R. Mikhael, Vivek Roy, Robert A. Kyle

Blood (2012) 119 (1): 44–48.

https://doi.org/10.1182/blood-2011-06-358895

Published: 2012

Journal Articles

Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,

Blood (2011) 118 (21): 3963.

https://doi.org/10.1182/blood.V118.21.3963.3963

Published: 2011

Journal Articles

Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,

Vishal Rana, MBBS, Geetika Srivastava, MBBS, Suzanne R Hayman, MD, Francis K Buadi, M.D., Morie A Gertz, MD, Martha Q Lacy, MD, Philip R. Greipp, MD, Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Robert A Kyle, MD, John A Lust, MD, PhD, Kristen Detweiler Short, N.P, David Dingli, M.D., Ph.D., Stephen J. Russell, S. Vincent Rajkumar, Shaji Kumar, MD

Blood (2011) 118 (21): 3981.

https://doi.org/10.1182/blood.V118.21.3981.3981

Published: 2011

Journal Articles

Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis

R. Donald Harvey, PharmD, Susanna Joan Jacobus, MSc, S. Vincent Rajkumar, MD, Philip R. Greipp, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1882.

https://doi.org/10.1182/blood.V118.21.1882.1882

Published: 2011

Journal Articles

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

John A Lust, MD, PhD, Martha Q Lacy, MD, Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Laurie L. Moon-Tasson, BA, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2011) 118 (21): 2945.

https://doi.org/10.1182/blood.V118.21.2945.2945

Published: 2011

Journal Articles

Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies

Prashant Kapoor, MD, Morie A Gertz, MD, S. Vincent Rajkumar, MD, Martha Q Lacy, MD, David Dingli, M.D., Ph.D., Suzanne R Hayman, MD, Stephen J. Russell, John A Lust, MD, PhD, Francis K Buadi, M.D., Steven R Zeldenrust, Philip R. Greipp, MD, Angela Dispenzieri, MD, Robert A Kyle, MD, Shaji Kumar, MD

Blood (2011) 118 (21): 2950.

https://doi.org/10.1182/blood.V118.21.2950.2950

Published: 2011

Journal Articles

IgD Amyloidosis: An Unrecognized Entity

Morie Abraham Gertz, MD, Francis K Buadi, M.D., Suzanne R Hayman, MD, David Dingli, M.D., Ph.D., Angela Dispenzieri, Philip R. Greipp, MD, Shaji Kumar, Martha Q Lacy, MD, John A Lust, MD, PhD, Nelson Leung, MD, S. Vincent Rajkumar, MD, Stephen J. Russell, MD, PhD, Steven R Zeldenrust, MD, PhD, Joseph R. Mikhael, MD, Vivek Roy, MD, FACP, Robert A Kyle, MD

Blood (2011) 118 (21): 5079.

https://doi.org/10.1182/blood.V118.21.5079.5079

Published: 2011

Journal Articles

The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis

Angela Dispenzieri, MD, Morie A Gertz, MD, Amy K Saenger, M.D., Martha Grogan, MD, Shaji Kumar, MD, Martha Q Lacy, MD, Robert A Kyle, MD, Nelson Leung, MD, Steven Zeldenrust, MD, Suzanne R Hayman, MD, Francis K Buadi, M.D., Philip R. Greipp, MD, S. Vincent Rajkumar, MD, Stephen Russell, MD, PhD, David Dingli, M.D., Ph.D., John A Lust, MD, PhD, Allan Jaffe, MD

Blood (2011) 118 (21): 2887.

https://doi.org/10.1182/blood.V118.21.2887.2887

Published: 2011

Journal Articles

Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort

Blood (2011) 118 (21): 2942.

https://doi.org/10.1182/blood.V118.21.2942.2942

Published: 2011

Journal Articles

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

Anita D'Souza, Suzanne R. Hayman, Francis Buadi, Michelle Mauermann, Martha Q. Lacy, Morie A. Gertz, Robert A. Kyle, Shaji Kumar, Philip R. Greipp, John A. Lust, Stephen J. Russell, Steven Zeldenrust, David Dingli, Thomas E. Witzig, S. Vincent Rajkumar, Angela Dispenzieri

Blood (2011) 118 (17): 4663–4665.

https://doi.org/10.1182/blood-2011-06-362392

Published: 2011

Journal Articles

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Shaji K. Kumar, Hajime Uno, Susanna J. Jacobus, Scott A. Van Wier, Greg J. Ahmann, Kimberly J. Henderson, Natalie S. Callander, Jessica L. Haug, David S. Siegel, Philip R. Greipp, Rafael Fonseca, S. Vincent Rajkumar

Blood (2011) 118 (16): 4359–4362.

https://doi.org/10.1182/blood-2011-03-342089

Published: 2011

Journal Articles

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Blood (2011) 118 (11): 2970–2975.

https://doi.org/10.1182/blood-2011-04-348896

Published: 2011

Journal Articles

Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival

Jeremy T. Larsen, Cheng E. Chee, John A. Lust, Philip R. Greipp, S. Vincent Rajkumar

Blood (2011) 118 (10): 2702–2707.

https://doi.org/10.1182/blood-2011-03-341933

Published: 2011

Journal Articles

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Sumit Madan, Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short, David Dingli, Steven Zeldenrust, John Lust, Philip R. Greipp, S. Vincent Rajkumar, Shaji Kumar

Blood (2011) 118 (7): 1763–1765.

https://doi.org/10.1182/blood-2011-04-350009

Published: 2011

Journal Articles

Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma

Sumit Madan, MD, Martha Lacy, MD, Angela Dispenzieri, MD, Morie Gertz, MD, Francis Buadi, MD, Suzanne R. Hayman, MD, Kristen Detweiler-Short, David Dingli, M.D., Ph.D., Steven Zeldenrust, MD, John Lust, MD, PhD, Philip R. Greipp, MD, S. Vincent Rajkumar, MD, Shaji Kumar, MD

Blood (2010) 116 (21): 1964.

https://doi.org/10.1182/blood.V116.21.1964.1964

Published: 2010

Journal Articles

Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score

Shaji Kumar, MD, Morie Gertz, MD, Martha Lacy, MD, David Dingli, MD, PhD, Suzanne R. Hayman, MD, Francis Buadi, MD, Kristen Detweiler-Short, Steven Zeldenrust, MD, Nelson Leung, MD, Philip R. Greipp, MD, John Lust, MD, PhD, Stephen Russell, MD, PhD, Robert Kyle, MD, Vincent Rajkumar, Angela Dispenzieri, MD

Blood (2010) 116 (21): 1892.

https://doi.org/10.1182/blood.V116.21.1892.1892

Published: 2010

NARROW

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma

Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial

Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)

Immunoglobulin D amyloidosis: a distinct entity

Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,

Factors Predicting Early Mortality in Patients with Newly Diagnosed Multiple Myeloma,

Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies

IgD Amyloidosis: An Unrecognized Entity

The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis

Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma

Recent Improvements In Survival In Light Chain Amyloidosis and the Importance of An Early Mortality Risk Score

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only